Skip to content
Peptide Atlas
All peptides

Tesamorelin

Tier 1 · Human trials
Also known as TH9507 · Egrifta

Efficacy and safety are supported by multiple randomized, multicenter, placebo-controlled Phase III trials (LIPO-010, CTR-1011) and their extension phases in HIV-associated lipodystrophy, plus FDA approval (2010). Detailed molecular/mechanistic descriptions (hexenoyl cap, GHRHR/Gs-cAMP/JAK2-STAT5 signaling) and regulatory history derive partly from lower-tier expert/clinic sources, some corroborated by tier 1 sources. Off-label uses (somatopause, NAFLD, cognitive impairment, orthopaedic) lack supporting clinical evidence.

Half-life
Not recorded
Routes
Subcutaneous injection (abdomen)
Goals
fat loss · gh stimulation · body composition
Cost / mg
Not recorded

How it works

Tesamorelin is a synthetic, stabilized version of growth hormone-releasing hormone (GHRH), the natural brain signal that tells the pituitary gland to release growth hormone. Rather than injecting growth hormone directly, tesamorelin prompts the body to release its own growth hormone in a natural, pulsing pattern. The extra growth hormone then drives the liver to make IGF-1 and promotes the breakdown of fat (lipolysis), which is why it reduces excess visceral (deep abdominal) fat in HIV-infected patients with lipodystrophy.

Overview

Overview

Tesamorelin (developmental code TH9507, marketed as Egrifta) is a stabilized synthetic analogue of the hypothalamic peptide growth hormone-releasing hormone (GHRH). It is a 44-amino-acid peptide (molecular weight ~5135.9 Da; formula C221H366N72O67S) developed by the Canadian biotech Theratechnologies (Montreal) and supplied as the acetate salt.

Regulatory Status

Tesamorelin was approved by the U.S. FDA on 10 November 2010 under the brand name Egrifta. It is the only GHRH analogue ever approved by the FDA for human use, and the only FDA-approved therapy to reduce excess abdominal fat in people with HIV. The European Medicines Agency granted centralized approval in July 2011, but marketing authorization was withdrawn at the sponsor's request in 2014 for commercial (not safety) reasons. It is now available in the US in a 2-mg per vial formulation (Egrifta SV); the formulation is also referenced as Egrifta WR.

Approved Indication

Tesamorelin is indicated to induce and maintain a reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. HIV-associated lipodystrophy is characterized by body-composition changes including lipohypertrophy with excess visceral adipose tissue (VAT), commonly associated with protease inhibitor use, which negatively affects body image and quality of life.

Mechanism

Rather than introducing exogenous human growth hormone, tesamorelin stimulates the release of the patient's own growth hormone in a natural pulsatile pattern by acting as a selective agonist at the GHRH receptor on anterior pituitary somatotrophs. The released GH drives hepatic IGF-1 synthesis and lipolysis, producing dose-dependent increases in IGF-1 and reductions in visceral fat. Because it works upstream at the pituitary, natural negative feedback is preserved.

Clinical Evidence

Efficacy was demonstrated in two randomized, multicenter, placebo-controlled Phase III trials (LIPO-010, N=412; CTR-1011, N=404), with a primary outcome of percent change in VAT at week 26. Enrollment required waist circumference ≥95 cm (males) / ≥94 cm (females), VAT >130 cm² by CT, and age 18–65.

  • Daily tesamorelin 2 mg for 26 weeks produced a significant decrease in VAT (~15% reduction) and improvement in lipids (P<0.001 vs baseline).
  • VAT reduction was sustained at ~18% over 52 weeks; a triglyceride change of about -51 mg/dL was sustained, with beneficial effects on total cholesterol and only minimal HDL decrease.
  • Subcutaneous adipose tissue and BMI were not clinically significantly affected (weight-neutral).
  • Clinical response (VAT decrease ≥8%) was achieved by approximately 70% of participants.
  • Beyond fat quantity, tesamorelin increased VAT density (+6.2 HU vs +0.3 HU placebo) and SAT density (+4.0 HU vs +0.3 HU placebo), improving fat quality.
  • Both trials showed significant improvements in some subjective body-image measures such as belly-image distress.

A separate 12-month study reported significant declines in visceral fat (median -25 cm² vs placebo +14 cm², P=0.001), hepatic fat (-4.2% vs -0.5%, P=0.01), and trunk-to-appendicular fat ratio (-0.1 vs 0.0, P=0.03), with beneficial effects and no exacerbation of glycemic control in patients on INSTI-based regimens.

Important Caveat: Reversibility

Upon discontinuation, VAT reaccumulates; effects on VAT are sustained during treatment but do not persist beyond the duration of therapy, implying that ongoing treatment is required to maintain benefit.

Off-Label and Investigational Uses

Outside its labeled indication, tesamorelin has been studied for age-related somatopause, non-alcoholic fatty liver disease (NAFLD), mild cognitive impairment, and metabolic syndrome. Supporting evidence for these is limited. A 6-month phase 2 open-label trial (N=73) showed only a non-significant trend toward improved neurocognitive performance (0.146; 95% CI -.002 to .294; P=.060) with no significant difference versus standard of care (P=.673), despite greater waist-circumference reduction (median difference -2.7 cm, P=.015). It has no supporting orthopaedic evidence, though GH secretagogues are discussed theoretically as possible adjuncts in orthopaedic injury.

Doping

Administration of tesamorelin and other GHRH synthetic analogs is prohibited by the World Anti-Doping Agency (WADA).

What the research shows

183 findings extracted from the 27 sources cited below, strongest evidence first within each group. Every one links to the source it came from.

What human studies found

Based on 57 human trial findings, 1 human study finding and 7 expert opinion findings.

  • human trialTesamorelin led to significant declines in visceral fat with median change of -25 cm2 compared to placebo +14 cm2 (P=0.001)2

  • human trialTesamorelin led to significant declines in hepatic fat with median change of -4.2% compared to placebo -0.5% (P=0.01)2

  • human trialTesamorelin led to significant declines in trunk-to-appendicular fat ratio with median change of -0.1 compared to placebo 0.0 (P=0.03)2

  • human trialTesamorelin had beneficial effects on body composition with no exacerbation of glycemic control in people on INSTI-based regimens2

  • human trialTesamorelin selectively reduced visceral fat by approximately 15% over 26 weeks and 18% over 52 weeks with no change in subcutaneous fat or BMI compared to placebo in prior Phase III trials2

  • human trialPrimary efficacy outcome for LIPO-010 and CTR-1011 was the per cent change in VAT at week 263

  • human trialSecondary efficacy outcomes included patient-reported outcomes (PROs) related to body image, specifically perceived belly size, belly appearance distress, and belly profile3

  • human trialOther relevant efficacy outcomes measured included waist circumference and quality of life3

Show the remaining 57

  • human trialTreatment of HIV patients with daily tesamorelin, a growth hormone-releasing factor analogue, for 26 weeks resulted in a significant decrease in visceral adipose tissue (VAT) and improvement in lipids4

  • human trialThe change in VAT was sustained at -18% over 52 weeks of treatment4

  • human trialChange in triglycerides was -51 mg/dl over 52 weeks of treatment4

  • human trialSimilar sustained beneficial effects were seen for total cholesterol, but high-density lipoprotein decreased minimally over 52 weeks4

  • human trialUpon discontinuation of tesamorelin, VAT reaccumulated4

  • human trialThough effects on VAT are sustained during treatment for 52 weeks, these effects do not last beyond the duration of treatment4

  • human trialTreatment of HIV patients with daily tesamorelin, a growth hormone releasing factor analogue, for 26 weeks resulted in a significant decrease in visceral adipose tissue (VAT) and improvement in lipids5

  • human trialThe change in VAT was sustained at 18% over 52 weeks of treatment versus baseline5

  • human trialTriglyceride change of -51 mg/dl was sustained over 52 weeks versus baseline5

  • human trialSimilar sustained beneficial effects were seen for total cholesterol5

  • human trialHigh-density lipoprotein decreased minimally over 52 weeks5

  • human trialUpon discontinuation of tesamorelin, VAT reaccumulated5

  • human trialTreatment with tesamorelin resulted in sustained decreases in VAT and triglycerides over 52 weeks without aggravating glucose5

  • human trialEffects on VAT are sustained during treatment for 52 weeks but do not last beyond the duration of treatment5

  • human trialAs May 2018, Theratechnologies announced that tesamorelin will enter a Phase 2b trial in patients7

  • human trialIn clinical trials in patients with HIV-associated lipodystrophy, tesamorelin therapy was not associated with de novo elevations in serum enzymes and in some studies was associated with decreases in preexisting ALT elevations8

  • human trialEfficacy of tesamorelin in the treatment of HIV-associated lipodystrophy shown in 2 randomized, multicenter, placebo-controlled trials9

  • human trialInsufficient evidence to support improved compliance with antiretroviral therapies in HIV-infected patients administered tesamorelin9

  • human trialTesamorelin reduces abdominal obesity12

  • human trialTesamorelin increases IGF-112

  • human trialTesamorelin showed a trend toward improved neurocognitive performance after 6 months in people with HIV and abdominal obesity12

  • human trialThe between-group difference in neurocognitive performance improvement was not significant between tesamorelin and standard of care groups12

  • human trialIGF-1 level increases with tesamorelin did not correlate with neurocognitive changes or waist circumference changes12

  • human trialTesamorelin group had greater reduction in waist circumference than standard of care group12

  • human trialShort-term abdominal obesity reduction with tesamorelin showed no clear benefit on neurocognitive impairment12

  • human trialPhase III clinical trials of tesamorelin were conducted prior to the introduction of integrase inhibitors (INSTIs)13

  • human trialTesamorelin 2 mg once daily led to significant declines in visceral fat compared to placebo in PWH on INSTI-based regimens13

  • human trialTesamorelin led to significant declines in hepatic fat compared to placebo13

  • human trialTesamorelin led to significant declines in trunk-to-appendicular fat ratio compared to placebo13

  • human trialOver 26 weeks, tesamorelin-treated participants showed mean VAT density increase of +6.2 (8.7) HU compared to +0.3 (4.2) HU in placebo (P < 0.0001)14

  • human trialOver 26 weeks, tesamorelin-treated participants showed mean SAT density increase of +4.0 (8.7) HU compared to +0.3 (4.8) HU in placebo (P < 0.0001)14

  • human trialTesamorelin improves VAT and SAT quality independent of changes in fat quantity in people living with HIV with central adiposity who experienced VAT quantity reductions14

  • human trialIn 2 Phase 3 clinical trials and their pooled analyses, tesamorelin was proven to significantly decrease waist circumference and visceral adipose tissue (VAT) following 26 weeks of treatment15

  • human trialBoth trials demonstrated significant improvements in some subjective body image parameters15

  • human trialBoth studies had 26-week extension phases that confirmed maintenance of VAT improvements on treatment without adverse impact on blood glucose and lipid parameters15

  • human trialLimited data support off-label uses of tesamorelin at this time15

  • human trialTesamorelin is effective in improving visceral adiposity and body image in patients with HIV-associated lipodystrophy over 26-52 weeks of treatment15

  • human trialSubcutaneous tesamorelin was effective in reducing visceral adipose tissue (VAT) in two 26-week, well designed, clinical trials in patients with HIV-associated central fat accumulation16

  • human trialTesamorelin did not affect subcutaneous adipose tissue to a clinically significant extent in the clinical trials16

  • human trialReduction in VAT was maintained in the longer term in patients who continued to receive tesamorelin until week 52 in the extension phases of the trials16

  • human trialDiscontinuation of tesamorelin therapy resulted in the reaccumulation of VAT16

  • human trialTesamorelin therapy was associated with significant improvements in other body composition measures such as trunk fat and waist circumference16

  • human trialTesamorelin therapy was associated with improvements in some body image parameters such as belly image distress16

  • human trialSubcutaneous tesamorelin was effective in reducing visceral adipose tissue (VAT) in two 26-week clinical trials in patients with HIV-associated central fat accumulation17

  • human trialTesamorelin did not affect subcutaneous adipose tissue to a clinically significant extent in the trials17

  • human trialReduction in VAT was maintained in patients who continued to receive tesamorelin until week 52 in the extension phases of the two trials17

  • human trialDiscontinuation of tesamorelin therapy resulted in reaccumulation of VAT17

  • human trialTesamorelin therapy was associated with significant improvements in trunk fat and waist circumference17

  • human trialTesamorelin therapy was associated with improvements in some body image parameters17

  • human studyTesamorelin is a long-lasting GHRH analogue that was shown effective in attenuating visceral fat and lipodystrophy in HIV-infected individuals taking highly active anti-retroviral therapy (HAART)7

  • expert opinionTesamorelin has no supporting orthopaedic evidence11

  • expert opiniontesamorelin is an approved drug by FDA (2010)20

  • expert opinionTesamorelin is the only growth hormone releasing hormone (GHRH) analogue ever approved by the FDA for human use25

  • expert opinionGreenlit in 2010 under the brand name Egrifta25

  • expert opinionThe compound was developed by the Canadian biotech Theratechnologies and received FDA approval on 10 November 2010 for the reduction of excess visceral adipose tissue (VAT) in HIV-infected patients with lipodystrophy25

  • expert opinionThe European Medicines Agency granted centralized approval in July 2011, but marketing authorization was withdrawn at the request of the sponsor in 2014 for commercial reasons (not safety)25

  • expert opinionTesamorelin received FDA approval in 2010 under the brand name Egrifta26

How it works

Based on 4 human trial findings, 1 human study finding, 21 expert opinion findings and 5 theoretical findings.

  • human trialTesamorelin is a growth hormone-releasing hormone12

  • human trialIn people with HIV who are virally suppressed, abdominal obesity is linked to neurocognitive impairment potentially due to visceral adiposity, inflammation, and reduced IGF-112

  • human trialTesamorelin is a growth hormone-releasing hormone analogue that reduces visceral fat (VAT) quantity in some people living with HIV14

  • human trialTesamorelin is a synthetic analog of human growth hormone-releasing hormone (also known as growth hormone-releasing factor) that stimulates the synthesis and release of endogenous growth hormone16

  • human studyTesamorelin is given subcutaneously and has major effects on glucose and lipid metabolism8

  • expert opinionTesamorelin is a synthetic analogue of growth hormone–releasing factor that triggers diverse metabolic effects, including lipolysis1

  • expert opinionTesamorelin is a growth hormone-releasing hormone analogue2

  • expert opinionTesamorelin is a synthetic analogue of growth hormone–releasing factor that triggers diverse metabolic effects, including lipolysis3

Show the remaining 23

  • expert opinionTesamorelin is a growth hormone-releasing factor analogue5

  • expert opinionSynthetic analog of human growth hormone-releasing factor (GHRF)9

  • expert opinionTesamorelin stimulates the release of endogenous growth hormone (GH), a known growth factor9

  • expert opinionTesamorelin injection is a hormone similar to the one normally released from the hypothalamus gland in the brain10

  • expert opinionTesamorelin is a synthetic analogue of human growth hormone-releasing hormone that stimulates the synthesis and release of endogenous growth hormone17

  • expert opinionSermorelin is a synthetic peptide in the growth hormone-releasing hormone (GHRH) class that has been studied for its ability to stimulate the body's own pituitary gland to produce and release growth hormone (GH)24

  • expert opinionSermorelin works upstream, prompting the hypothalamic-pituitary axis to increase its natural GH output through existing physiological feedback mechanisms, unlike exogenous GH administration which introduces synthetic hormone directly into the body24

  • expert opinionSermorelin (sermorelin acetate) is a 29-amino acid peptide representing the biologically active fragment of endogenous GHRH24

  • expert opinionSermorelin's mechanism of action centers on pituitary stimulation rather than GH replacement24

  • expert opinionSermorelin binds to pituitary GHRH receptors and mimics the endogenous signal, prompting increased GH secretion within the body's existing regulatory24

  • expert opinionIt stimulates the pituitary to release endogenous growth hormone in physiological, pulsatile patterns rather than flooding the body with exogenous human growth hormone (HGH)25

  • expert opinionTesamorelin is a selective agonist at the GHRH receptor (GHRHR), a class B G protein-coupled receptor expressed predominantly on somatotroph cells in the anterior pituitary25

  • expert opinionBinding activates adenylate cyclase through Gs alpha coupling, elevating intracellular cyclic AMP and triggering the release of stored growth hormone (GH) from secretory granules25

  • expert opinionThe released GH then acts systemically, most importantly on hepatocytes, where it induces insulin-like growth factor 1 (IGF-1) synthesis via JAK2 / STAT5 signaling25

  • expert opinionBecause Tesamorelin works upstream of the pituitary rather than replacing GH directly, the resulting GH profile preserves the body's natural negative feedback25

  • expert opinionTesamorelin is classified as a Growth Hormone-Releasing Hormone (GHRH) analog26

  • expert opinionTesamorelin acts as a secretagogue that instructs the pituitary gland to release its own endogenous stores of growth hormone in a natural, pulsatile manner26

  • expert opinionPeptides are short chains of amino acids with a unique pharmacological niche between small-molecule drugs and large proteins27

  • theoreticalTesamorelin is a synthetic 44 amino acid polypeptide analogue of growth hormone releasing hormone (GHRH)8

  • theoreticalTesamorelin activates GHRH receptors in the pituitary which leads to synthesis and release of growth hormone that acts on multiple cells of the body including hepatocytes where it stimulates production of insulin like growth factor-1 (IGF-1)8

  • theoreticaltesamorelin is a stabilized synthetic peptide analogue of the hypothalamic peptide GHRH20

  • theoreticalTesamorelin is a growth hormone secretagogue that activates IGF-1 signaling and satellite cell repair21

  • theoreticalTesamorelin is a synthetic analog of growth hormone releasing hormone (GHRH)22

Dosing

Based on 3 human trial findings, 1 human study finding and 5 expert opinion findings.

  • human trialTesamorelin 2 mg/day (subcutaneous injection) compared to placebo in randomized controlled trials3

  • human trialTesamorelin 2 mg s.c. daily for 26 weeks significantly reduced VAT5

  • human trialTesamorelin is administered subcutaneously19

  • human studyThe recommended dose is 2 mg daily given by subcutaneous injection8

  • expert opinionAdminister sub-Q into the abdomen once daily9

  • expert opinionThis medicine is given as a shot under the skin of your stomach10

  • expert opinionUse a different body area each time you give yourself a shot10

  • expert opinionDo not inject into skin areas with scar tissue, hard bumps, or bruises, or into your belly button10

Show the remaining 1

  • expert opinionUse a new needle and syringe each time you inject your medicine10

How the body handles it

Based on 4 human trial findings, 2 human study findings, 2 in vitro findings, 5 expert opinion findings and 2 theoretical findings.

  • human trial2-mg per vial formulation (Egrifta SV) that is given as a 1.4-mg dose has demonstrated comparable bioavailability to the 1-mg/vial formulation (Egrifta)9

  • human trialTesamorelin increases growth hormone levels in healthy subjects19

  • human trialTesamorelin increases IGF-1 levels in healthy subjects in a dose-dependent manner19

  • human trialAge is an intrinsic factor affecting pharmacokinetics and pharmacodynamics of tesamorelin19

  • human studyTesamorelin has different pharmacokinetic characteristics in HIV-infected patients compared to healthy subjects19

  • human studyTesamorelin increases IGF-1 levels in HIV-infected patients19

  • in vitroNineteen major in vitro metabolites of tesamorelin were identified22

  • in vitroA liquid chromatography-tandem mass spectrometry method was developed to detect tesamorelin with limits of detection of 1 ng/ml or less22

Show the remaining 7

  • expert opinionThe approved formulation is the acetate salt20

  • expert opinionGHRH synthetic analogs do not appear to have been found in anti-doping samples by WADA accredited laboratories, possibly due to small concentration in urine and limited knowledge about their metabolism22

  • expert opinionNative GHRH has a plasma half life of only a few minutes because DPP-IV cleaves the first two residues on contact25

  • expert opinionThe hexenoyl cap roughly triples the plasma persistence of Tesamorelin without altering its receptor binding profile25

  • expert opinionNatural GHRH has an incredibly short half-life measured in mere minutes because it is rapidly degraded by dipeptidyl peptidase-4 (DPP-4)26

  • theoreticalThe N terminal portion of the molecule has been modified to improve its stability and pharmacokinetics in comparison to native GHRH8

  • theoreticalTesamorelin is a synthetic polypeptide that acts upon growth hormone producing cells in the pituitary and is generally metabolized locally by the receptor bearing cells8

Safety and side effects

Based on 14 human trial findings, 5 human study findings and 14 expert opinion findings.

  • human trialTesamorelin was well-tolerated with a similar frequency of adverse events including hyperglycemia between groups2

  • human trialChanges in glucose parameters over 52 weeks were not clinically significant4

  • human trialTesamorelin was generally well tolerated4

  • human trialThe prevalence of adverse events and serious adverse events during the extension phase was comparable with the initial phase4

  • human trialTesamorelin was generally well tolerated5

  • human trialChanges in glucose parameters over 52 weeks were not clinically significant and similar to those after 26 weeks5

  • human trialLong-term cardiovascular safety not established9

  • human trialTesamorelin was well tolerated with a similar frequency of adverse events, including hyperglycemia, between tesamorelin and placebo groups13

Show the remaining 25

  • human trialTesamorelin was generally well tolerated with treatment-emergent serious adverse events occurring in less than 4% of patients during 26 weeks of therapy16

  • human trialMost serious adverse events were injection-site reactions or events known to be associated with growth hormone therapy such as arthralgia, headache and peripheral edema16

  • human trialTreatment-emergent serious adverse events occurred in <4% of patients during 26 weeks of therapy17

  • human trialMost treatment-emergent serious adverse events were injection-site reactions or events known to be associated with growth hormone therapy such as arthralgia, headache and peripheral oedema17

  • human trialImmunogenicity affects the pharmacokinetics of tesamorelin19

  • human trialTesamorelin has been studied for drug-drug interactions19

  • human studyTesamorelin has not been linked to serum aminotransferase elevations during therapy or to instances of clinically apparent acute liver injury8

  • human studySide effects include injection site reactions, itching, arthralgia, myalgia and peripheral edema8

  • human studyTesamorelin raises IGF-1 levels and monitoring for elevations during therapy is recommended8

  • human studyPotential rare adverse events include stimulation of malignant tumor growth, glucose intolerance, diabetes and hypersensitivity reactions8

  • human studyInstances of clinically apparent liver injury attributable to tesamorelin use have not been reported8

  • expert opinionMonitor patients periodically during treatment for development of impaired glucose tolerance or diabetes9

  • expert opinionMonitor patients with diabetes at regular intervals for development or worsening of retinopathy9

  • expert opinionMonitor for signs and symptoms of hypersensitivity reactions (pruritus, erythema, flushing, urticaria, rash)9

  • expert opinionContraindicated in patients with disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, pituitary tumor/surgery, head irradiation, or head trauma9

  • expert opinionContraindicated in active malignancy9

  • expert opinionContraindicated in pregnant women9

  • expert opinionShould not be used in patients with pituitary gland tumor or surgery10

  • expert opinionShould not be used in patients with active or history of cancer10

  • expert opinionShould not be used in patients with allergy to mannitol history10

  • expert opinionUse with caution in patients with breathing problems, lung disease, carpal tunnel syndrome, diabetes, edema, heart surgery history, retinopathy, stomach surgery history, or trauma10

  • expert opinionSafety and efficacy have not been established in children10

  • expert opinionPotential limitations for its use include high cost and lack of long-term safety and adherence data15

  • expert opinionAdministration of tesamorelin and other GHRH synthetic analogs is prohibited by the World Anti-Doping Agency (WADA)22

  • expert opinionTesamorelin has undergone a rigorous approval process that evaluates both safety and efficacy27

What people use it for

Based on 9 human trial findings, 9 human study findings, 7 expert opinion findings and 1 theoretical finding.

  • human trialTesamorelin is indicated for treatment of excess visceral adipose tissue (VAT) in treatment-experienced adult HIV-infected patients with lipodystrophy1

  • human trialTesamorelin is the only FDA-approved therapy to treat abdominal fat accumulation in people with HIV2

  • human trialTesamorelin is a growth hormone releasing factor (GRF) analog used to reduce excessive abdominal fat in HIV patients who have developed lipodystrophy6

  • human trialHas a weight neutral effect9

  • human trialClinical response to tesamorelin was defined as VAT decrease ≥8%, achieved by approximately 70% of participants14

  • human trialTesamorelin is a growth hormone releasing factor analogue approved by the Food and Drug Administration in November 2010 for the treatment of lipodystrophy associated with HIV infection15

  • human trialTesamorelin is the first and only treatment indicated for the reduction of excess abdominal fat in patients with HIV-associated lipodystrophy16

  • human trialtesamorelin (Egrifta; Theratechnologies/EMD Serono), a growth hormone-releasing factor analogue, was approved by the US Food and Drug Administration for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy18

Show the remaining 18

  • human trialTesamorelin is a growth hormone-releasing hormone (GHRH) analog indicated to induce and maintain a reduction of excess abdominal fat in HIV-infected patients with lipodystrophy19

  • human studyHuman immunodeficiency virus (HIV)–associated lipodystrophy is characterized by body composition changes, including lipohypertrophy with excess visceral adipose tissue (VAT)1

  • human studyUse of protease inhibitors is commonly associated with the development of lipohypertrophy1

  • human studyExcess VAT negatively affects patients' body image and quality of life (QoL)1

  • human studyHIV–associated lipodystrophy is characterized by body composition changes, including lipohypertrophy3

  • human studyProtease inhibitors are commonly associated with the development of lipohypertrophy3

  • human studyTesamorelin is an analog of growth hormone-releasing hormone used as a subcutaneous treatment to reduce excess abdominal fat in HIV-infected patients with lipodystrophy7

  • human studyTesamorelin is a synthetic growth hormone releasing hormone analogue used in the treatment of visceral adiposity in human immunodeficiency virus (HIV) infected patients with lipodystrophy8

  • human studyTesamorelin was approved for use in the United States as therapy to reduce excess abdominal fat in HIV-infected patients with antiviral therapy-related lipodystrophy in 20108

  • human studyIt is used to reduce excess fat (lipodystrophy) in the stomach area in patients with human immunodeficiency virus (HIV) infection10

  • expert opinionTesamorelin may sometimes be given at home to patients who do not need to be in a hospital or clinic10

  • expert opinionTesamorelin is approved for treating HIV-associated lipodystrophy11

  • expert opinionTesamorelin is the only FDA-approved therapy to treat abdominal fat accumulation in people with HIV13

  • expert opinionTesamorelin is the first and only treatment indicated for the reduction of excess abdominal fat in patients with HIV-associated lipodystrophy17

  • expert opinionSermorelin was originally developed and FDA-approved in the 1990s under the brand name Geref for the diagnosis and treatment of growth hormone deficiency in children24

  • expert opinionOutside of that labeled indication, Tesamorelin has been studied for age-related somatopause, non-alcoholic fatty liver disease (NAFLD), mild cognitive impairment and metabolic syndrome25

  • expert opinionTesamorelin (Egrifta) is a peptide marketed direct to patients27

  • theoreticalGrowth hormone secretagogues like tesamorelin are emerging as promising adjuncts in the management of orthopaedic injuries21

Other findings

Based on 1 human trial finding and 3 expert opinion findings.

  • human trialBrand name is Egrifta6

  • expert opinionThe molecular weight is approximately 5135.9 Da25

  • expert opinionTesamorelin was developed by Theratechnologies Inc., a Canadian biopharmaceutical company based in Montreal26

  • expert opinionTesamorelin has a developmental code name TH950726

Points of contention

Where the evidence is unsettled, thin, or says less than the popular claim — worth knowing before you draw conclusions.

Limited evidence

VAT benefits reverse after stopping treatment.

Multiple trial sources report that upon discontinuation of tesamorelin, VAT reaccumulated, and effects on VAT do not last beyond the duration of treatment, implying ongoing therapy is required to maintain the benefit.

Limited evidence

Long-term cardiovascular safety and adherence data are lacking.

Sources note long-term cardiovascular safety is not established, and cite high cost plus lack of long-term safety and adherence data as limitations for use.

Limited evidence

Neurocognitive benefit was not demonstrated.

A phase 2 trial (Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.) found only a non-significant trend toward improved neurocognitive performance with tesamorelin (P=.060) and no significant between-group difference versus standard of care (P=.673), despite significant waist circumference reduction.

Limited evidence

Off-label and orthopaedic uses lack supporting evidence.

Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. states limited data support off-label uses; Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. states tesamorelin has no supporting orthopaedic evidence; while Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. (tier 2) frames GH secretagogues as promising adjuncts for orthopaedic injury on a theoretical basis. Tesamorelin Dosing Guide: GHRH Analogue Research Protocols lists somatopause, NAFLD, cognitive impairment and metabolic syndrome only as areas studied.

Single source

Detailed molecular/mechanistic and regulatory-history details come from lower-tier sources.

Molecular weight (~5135.9 Da), hexenoyl cap tripling plasma persistence, GHRHR/Gs-cAMP/JAK2-STAT5 signaling detail, and the 2014 EMA withdrawal for commercial reasons derive largely from tier 3 blog/clinic sources (Tesamorelin Dosing Guide: GHRH Analogue Research Protocols, The Ultimate Guide to Tesamorelin | Las Vegas | Sky Health); some mechanistic detail is corroborated by tier 1 Tesamorelin - LiverTox - NCBI Bookshelf.

Limited evidence

INSTI-era efficacy data come from a small trial.

Prior pivotal Phase III trials predated integrase inhibitors; the INSTI-era evidence (Efficacy and Safety of Tesamorelin in People with HIV on Integrase Inhibitors - PMC, Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.) comes from a small 12-month study (61 participants, with only 15 tesamorelin and 16 placebo completers), limiting the strength of the conclusion that glycemic control is not worsened on INSTI regimens.

Contested

Reported CAS numbers differ between sources.

Tesamorelin Dosing Guide: GHRH Analogue Research Protocols lists CAS 218949-48-5 while Tesamorelin - LiverTox - NCBI Bookshelf lists CAS 901758-09-6 for tesamorelin.

What you may have heard

"The only GHRH analogue ever approved by the FDA for human use" stated as bold fact.

Sermorelin acetate (Geref), a GHRH(1-29) analogue, was FDA-approved in 1997 for diagnostic and pediatric GHD use before being discontinued. Tesamorelin is arguably the only GHRH analogue currently marketed / approved for this indication, but the sweeping "ever approved for human use" claim is factually wrong. It rests solely on tier-3 blog source Tesamorelin Dosing Guide: GHRH Analogue Research Protocols.

Inconsistency

Recommended dose stated as 2 mg daily, but Egrifta SV described as "given as a 1.4-mg dose," and old vial as 1 mg / 1.1 …

The profile simultaneously says the recommended dose is 2 mg daily (claim 56), that the SV formulation is given as 1.4 mg with bioavailability comparable to the 1-mg vial (claim 24), and that the lyophilized powder contains 1.1 mg acetate (claim 75). A reader cannot reconcile whether the patient receives 1 mg, 1.4 mg, or 2 mg of active tesamorelin. This needs disambiguation (free-base vs acetate salt, and formulation-specific delivered dose).

Other

Several efficacy figures (VAT ~15%, lipids P<0.001, triglyceride -51 mg/dL over 52 weeks) are within-group vs-baseline c…

Claims 37–39 explicitly state "versus baseline." The 52-week extension was largely open-label/uncontrolled, so within-group changes overstate the causal effect attributable to tesamorelin relative to placebo. The prose presents these alongside placebo-controlled data without flagging the distinction.

What you may have heard

"Generally metabolized locally by the receptor-bearing cells" is a biochemically dubious statement.

Peptide GHRH analogues are cleared primarily by circulating and tissue peptidases (notably DPP-IV) and renal/hepatic proteolysis, not by "local metabolism at receptor-bearing cells." The phrasing (from Tesamorelin - LiverTox - NCBI Bookshelf) is vague and potentially misleading about clearance mechanism.

Other

No numeric half-life given, though a well-characterized value exists.

Tesamorelin's plasma half-life (~26–38 min in reported PK studies) supports the once-daily dosing rationale (short pulse to preserve pulsatility). Stating only that it "roughly triples" GHRH persistence leaves the reader without the actual figure that justifies daily administration.

What you may have heard

12-month INSTI-era findings presented with firm P-values despite very small completer numbers.

The stated caveat notes the INSTI study had only ~15 tesamorelin and ~16 placebo completers, yet the overview reports median VAT/hepatic-fat/ratio changes with P-values as robust confirmation that glycemic control is not worsened. The small n should be surfaced in the prose, not only the caveat block.

Contested

Injection sites should be rotated using a new needle and syringe each time, avoiding scar tissue, hard bumps, bruises, o…

While the source material supports most of the statement's components individually—including rotating injection sites, using a new needle and syringe each time, and avoiding scar tissue, hard bumps, bruises, and the belly button—the source does not explicitly state that rotation should be done 'using a new needle and syringe each time' as a single integrated instruction. The source lists these as separate guidance items: 'Use a different body area each time you give yourself a shot' and separately 'Use a new needle and syringe each time you inject your medicine.' The statement combines these into one directive about rotation that is not explicitly stated together in the source material in this exact formulation.

Inconsistency

Tesamorelin appears in reference databases under two different CAS registry numbers, which is not a real inconsistency.

A US National Library of Medicine record (LiverTox) lists tesamorelin under CAS 901758-09-6 with a molecular formula that carries an added acetate component, while a vendor research dosing guide lists CAS 218949-48-5 for the plain 44-amino-acid peptide (molecular weight ~5135.9 Da). The two numbers reflect the free peptide versus its acetate salt — the acetate form is what is actually supplied as the drug — rather than a contradiction. The core peptide formula, C221H366N72O67S, is consistent across chemical-structure databases.

Contested

Tesamorelin was approved by the U.S. FDA in 2010 following review of its safety and efficacy for its labeled indication;…

The source material confirms that tesamorelin has undergone a rigorous approval process evaluating safety and efficacy, and that it is marketed direct to patients. However, the source does not specify the year 2010 as the FDA approval date, nor does it address whether the label characterizes the product's marketing or the approval process. The statement makes specific claims about the approval year and label characterization that are not present in the provided source material.

Single source

The one source cited for this claim confirms tesamorelin went through a rigorous approval process but never states the 2010 date or describes what the label says.

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance., a tier-3 narrative review, states only that tesamorelin (Egrifta) is a peptide marketed direct to patients and that it underwent a rigorous approval process evaluating both safety and efficacy. It does not specify the November 2010 FDA approval date, nor does it make any statement about whether the label characterizes the product's marketing or the approval process. Those elements of the claim rest on no cited source here and cannot be verified against Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance..

Using it with other compounds

Check a stack
  • TirzepatideComplementary

    Worth caution

    Tirzepatide's dual GIP/GLP-1 action reduces fat mass and improves insulin sensitivity through gut-hormone receptors, distinct from tesamorelin's GH axis. The two can converge on visceral/metabolic fat loss, and tirzepatide's insulin-sensitizing effect may counter GH-induced glucose elevation, but blood glucose still warrants monitoring on the combination.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms support a complementary relationship on the shared dimension of lipolysis. Tesamorelin achieves lipolysis through GH axis activation (GHRHR → cAMP → GH release → IGF-1 signaling), with documented reduction of visceral adipose tissue and hepatic fat. Tirzepatide achieves lipolysis through dual GIP/GLP-1 receptor activation leading to body weight and fat mass reduction via appetite suppression and improved insulin sensitivity. The mechanisms are distinct (GH axis vs. gut-hormone receptors) yet both converge on fat loss outcomes. The explanation correctly identifies this as complementary rather than redundant, and the caveat about glucose monitoring reflects the known pharmacology without contradicting the mechanism descriptions provided.

    Shares lipolysis

  • IpamorelinSame downstream effect

    May be complementary

    Tesamorelin is a stabilized GHRH analog acting on the GHRH receptor — a distinct mechanism from ipamorelin's ghrelin receptor — but both raise GH/IGF-1 and support fat loss. Combining a GHRH-side driver with ipamorelin's ghrelin-side amplification produces a larger GH pulse, and tesamorelin's specific strength in reducing visceral fat can complement ipamorelin's reported lipolysis for body-composition goals.

    Tier 2Supported by animal / early studies

    What the research doesn't fully establish

    The mechanism descriptions clearly establish that both peptides converge on shared downstream pathways despite distinct receptor targets. Ipamorelin acts via GHSR-1a (ghrelin receptor) while tesamorelin acts via GHRHR (GHRH receptor)—these are indeed different upstream mechanisms. However, both demonstrably activate the GH_axis (pulsatile GH release from anterior pituitary somatotrophs), both elevate IGF-1 (ipamorelin via GH→IGF-1 signaling; tesamorelin via hepatic JAK2/STAT5 induction), both engage cAMP_PKA signaling (ipamorelin explicitly lists cAMP/PKA; tesamorelin's Gs-alpha/adenylate cyclase/cAMP pathway activates PKA), and both produce lipolysis effects. The shared_downstream relationship type is justified: the peptides use different receptors but converge on common effector pathways and biological outcomes. The four claimed shared dimensions (GH_axis, IGF1_signaling, cAMP_PKA, lipolysis) are all explicitly supported in the mechanism material for both peptides. The explanation accurately describes the complementary nature of their distinct mechanisms feeding into overlapping downstream biology.

    Timing Administer together on an empty stomach; nighttime dosing aligns with natural GH pulses.

    Shares GH axis · IGF1 signaling · cAMP PKA · lipolysis

  • CJC-1295Same mechanism

    Worth caution

    Tesamorelin is also a stabilized GHRH analog acting on the same GHRH-R/cAMP pathway to raise GH and IGF-1. Combining it with CJC-1295 stacks two drugs doing the identical job, which is redundant and could over-drive IGF-1 without adding a distinct benefit. Choose one GHRH agent for a given goal.

    Tier 3Largely anecdotal — commonly discussed

    What the research doesn't fully establish

    Both peptides' mechanisms clearly establish they target the same GHRH receptor (GHRH-R/GHRHR) on anterior-pituitary somatotrophs and activate the identical cAMP-dependent signaling cascade (Gs-alpha/adenylate cyclase/cAMP/PKA pathway). Both produce dose-dependent increases in GH secretion and IGF-1 levels through the same endocrine axis. The shared mechanism tags (GH_axis, IGF1_signaling, cAMP_PKA) are explicitly supported by both descriptions. The proposed relationship correctly identifies that both are GHRH analogs operating through the same receptor and pathway, making them mechanistically redundant rather than complementary. The explanation's logic about stacking two agents with identical mechanisms is justified by the provided mechanism material.

    Timing Avoid running two GHRH analogs at once; select one.

    Shares GH axis · IGF1 signaling · cAMP PKA

  • SermorelinSame mechanism

    Worth caution

    Tesamorelin is also a GHRH-receptor agonist working through the identical Gs/cAMP pathway to release endogenous GH. Combining it with sermorelin is redundant — both compete for the same receptor and effect, so you gain little over choosing the stronger/more targeted single agent (tesamorelin is the visceral-fat specialist).

    Tier 3Largely anecdotal — commonly discussed

    What the research doesn't fully establish

    Both peptides' mechanisms clearly establish they are GHRH receptor agonists (Sermorelin targets GHRH receptor on somatotrophs; Tesamorelin targets GHRHR class B GPCR). Both activate identical signaling pathways: Gs/adenylyl cyclase/cAMP leading to pulsatile GH release from anterior pituitary somatotrophs. Both share all four claimed dimensions in their approved tags: GH_axis, lipolysis, IGF1_signaling, and cAMP_PKA. The mechanism descriptions explicitly confirm both work through the same receptor and same second-messenger cascade to achieve endogenous GH stimulation. The explanation's characterization of functional redundancy at the receptor level is directly supported by the provided mechanisms.

    Shares GH axis · lipolysis · IGF1 signaling · cAMP PKA

  • MOTS-cComplementary

    No documented conflict

    Both reduce adiposity, especially visceral and hepatic fat, but through unrelated mechanisms: tesamorelin raises GH/IGF-1 to drive lipolysis, while MOTS-c acts through AMPK-driven metabolism and adipose browning. These non-overlapping fat-loss pathways can complement each other for body-composition goals.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms clearly support lipolysis as a shared dimension with complementary (non-overlapping) pathways. MOTS-c mechanisms include AMPK activation, white adipose tissue browning/thermogenesis, and reduced fat mass via metabolic reprogramming. Tesamorelin mechanisms include GH/IGF-1 axis activation driving lipolysis and visceral fat reduction via Gs-alpha/cAMP/PKA signaling. The proposed explanation accurately reflects these distinct mechanistic routes to fat loss, and both peptides are tagged with 'lipolysis,' confirming this shared dimension. The claim that these pathways are unrelated and complementary is well-supported by the non-overlapping receptor targets (NFE2L2/Keap1/AMPK for MOTS-c vs. GHRHR/GH/IGF-1 for tesamorelin) and distinct downstream signaling cascades described in the mechanisms.

    Shares lipolysis

  • SemaglutideComplementary

    Worth caution

    Both reduce fat but by unrelated mechanisms — semaglutide via appetite/energy-intake reduction and tesamorelin via GH-driven lipolysis targeting visceral and liver fat. They can be complementary for body-composition goals, but growth hormone tends to raise blood glucose and lower insulin sensitivity, which works against semaglutide's glycemic benefit, so blood sugar should be monitored.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms clearly support lipolysis as a shared dimension: Semaglutide produces 'Weight loss / reduction in body weight and visceral fat' and carries the 'lipolysis' tag. Tesamorelin explicitly targets 'Reduction of visceral (abdominal) adipose tissue, Lipolysis' and 'Reduction of hepatic fat' with the 'lipolysis' tag. The proposed explanation correctly identifies that they achieve lipolysis through distinct mechanisms (semaglutide via appetite suppression/energy intake; tesamorelin via GH-axis/IGF-1 signaling), which justifies the 'complementary' relationship type. The caveat about potential glucose/insulin sensitivity interactions is reasonable given semaglutide's glucose-dependent insulin secretion pathway versus tesamorelin's GH effects, though this represents a potential limitation rather than contradicting the complementary relationship for lipolysis-focused goals.

    Shares lipolysis

  • AOD-9604Complementary

    May be complementary

    Both push fat loss but by different routes: tesamorelin raises endogenous growth hormone via the GHRH receptor, while AOD-9604 stimulates fat breakdown directly in fat cells (cAMP rise, hormone-sensitive lipase) without acting on the GH receptor. Because their entry points differ, they can reinforce each other on the same goal of reducing (especially visceral) fat.

    Tier 3Largely anecdotal — commonly discussed

    What the research doesn't fully establish

    The mechanisms clearly establish complementary action on the two shared dimensions. Both peptides elevate cAMP and promote lipolysis, but through distinct pathways: Tesamorelin acts via GHRHR → GH release → IGF-1 signaling → lipolysis, while AOD-9604 acts via beta3-AR → direct cAMP elevation → hormone-sensitive lipase activation → lipolysis. The mechanism descriptions explicitly confirm AOD-9604 does NOT meaningfully bind the classical hGH receptor, and Tesamorelin's effects are GH-axis dependent, confirming their entry points are genuinely different. Both converge on cAMP_PKA and lipolysis as endpoints, making them mechanistically complementary rather than redundant. The explanation accurately reflects the provided mechanisms.

    Timing No strict separation needed; both are commonly dosed on an empty stomach/subcutaneously.

    Shares lipolysis · cAMP PKA

  • HexarelinSame downstream effect

    May be complementary

    Tesamorelin is a stabilized GHRH analog; hexarelin is a GHS-R1a secretagogue. They act on distinct receptors that both drive pituitary GH release, so combined they can produce a larger, more physiologic GH/IGF-1 response — with tesamorelin adding a documented visceral-fat-lowering effect. Monitor IGF-1 since two upstream drivers stacking can push it higher than intended.

    Tier 2Supported by animal / early studies

    What the research doesn't fully establish

    Both peptides' mechanisms clearly converge on the GH/IGF-1 axis despite distinct receptor targets. Hexarelin targets GHS-R1a and stimulates pulsatile GH release and increases IGF-1 with prolonged administration. Tesamorelin targets GHRHR and increases endogenous GH (pulsatile release) with dose-dependent IGF-1 increase. The mechanisms establish they act on different upstream receptors (GHS-R1a vs GHRHR) but both drive the same downstream GH secretion and IGF-1 signaling pathway. Lipolysis is explicitly documented for tesamorelin (visceral adipose tissue reduction, hepatic fat reduction). While hexarelin's mechanism material does not explicitly list lipolysis as an effect, the shared GH_axis and IGF1_signaling dimensions are clearly supported. The proposed relationship correctly identifies that these are distinct upstream drivers converging on common downstream GH/IGF-1 signaling, making 'same_downstream' an accurate characterization. The explanation's concern about stacking effects on IGF-1 is mechanistically sound given both peptides independently increase IGF-1 through the same axis.

    Timing Co-inject on an empty stomach; keep IGF-1 in a sensible range with periodic monitoring.

    Shares GH axis · IGF1 signaling · lipolysis

  • MK-677Same downstream effect

    Worth caution

    Tesamorelin is a stabilized GHRH analog that raises GH/IGF-1 through the GHRH receptor, distinct from MK-677's ghrelin-receptor pathway. Both feed the same GH/IGF-1 axis, so they can be additive on GH output. Note a practical tension: tesamorelin is used specifically to reduce visceral fat, whereas MK-677 raises appetite and can promote fluid retention and insulin resistance, which may partly counter the body-composition goal.

    Tier 3Largely anecdotal — commonly discussed

    What the research doesn't fully establish

    Both peptides' mechanisms clearly converge on the GH/IGF-1 axis as a shared downstream endpoint, despite distinct upstream targets (GHS-R1a vs GHRHR). MK-677 mechanisms show 'GH-vesicle exocytosis in pituitary somatotrophs' and 'GH/IGF-1 axis (IGF-1, IGFBP-3 elevation)' with approved tags including GH_axis and IGF1_signaling. Tesamorelin mechanisms show 'GH release from anterior pituitary somatotrophs' and 'Hepatic JAK2/STAT5 induction of IGF-1' with matching approved tags GH_axis and IGF1_signaling. Both mechanisms explicitly document IGF-1 elevation. Regarding lipolysis: Tesamorelin's mechanisms explicitly list 'Lipolysis' and 'Reduction of visceral adipose tissue' as effects. MK-677's mechanisms do not explicitly mention lipolysis as a direct effect—it lists 'Increased fat-free/lean mass' and 'Reversal of diet-induced protein catabolism,' which are anabolic rather than lipolytic. The claim of shared lipolysis dimension is therefore only partially supported by the provided mechanisms (supported for tesamorelin, not documented for MK-677). However, the core same_downstream relationship on GH_axis and IGF1_signaling is clearly justified by both mechanisms converging on pituitary GH release and subsequent IGF-1 elevation through distinct receptor pathways.

    Timing Monitor fasting glucose/insulin, since both GH-raising agents plus MK-677's appetite drive can worsen insulin sensitivity.

    Shares GH axis · IGF1 signaling · lipolysis

  • KlothoStack with caution

    Worth caution

    Tesamorelin dose-dependently elevates IGF-1 via GH release, while Klotho tends to suppress IGF-1/insulin signaling as part of its longevity effects. The opposing directions on IGF-1 mean this is a mechanistic tension to be aware of if Klotho is being used for anti-senescence goals, even though tesamorelin's fat-loss benefit is unrelated.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    The proposed relationship claims Klotho 'tends to suppress IGF-1/insulin signaling as part of its longevity effects,' but Klotho's mechanism description explicitly lists 'IGF-1/insulin receptor signaling axis' as a target and 'Improved insulin sensitivity/secretion (preclinical)' as an effect, with 'IGF1_signaling' as an approved tag. This indicates Klotho modulates/enhances IGF-1 signaling, not suppresses it. Both peptides therefore share the dimension of IGF-1 signaling elevation rather than opposing directions. The mechanistic tension claimed in the explanation is not supported by the provided mechanism material.

    Shares IGF1 signaling

  • Follistatin-344Complementary

    May be complementary

    Tesamorelin raises GH/IGF-1 and preferentially strips visceral fat, while Follistatin adds muscle mass and reduces adiposity by blocking myostatin. Their combined effect leans toward improved body composition (more lean mass, less fat) through distinct pathways.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms establish IGF1_signaling as a shared dimension: Follistatin explicitly lists IGF-1R signaling as a partial mediator of hypertrophy (approved tag: IGF1_signaling), and Tesamorelin's mechanism directly increases endogenous IGF-1 via GH release and hepatic JAK2/STAT5 induction (approved tag: IGF1_signaling). The proposed complementary relationship is justified—they operate through distinct primary mechanisms (ligand sequestration vs. GHRH receptor activation) but converge on IGF-1 signaling to promote anabolic effects. The explanation accurately reflects that Follistatin drives muscle hypertrophy and reduces adiposity through TGF-beta antagonism while Tesamorelin increases GH/IGF-1 and preferentially targets visceral fat through cAMP/GH axis activation, making them mechanistically complementary for body composition improvement.

    Shares IGF1 signaling

Safety and side effects

Safety and Tolerability

Across the pivotal Phase III trials and extension phases, tesamorelin was generally well tolerated. Treatment-emergent serious adverse events occurred in less than 4% of patients during 26 weeks of therapy, most commonly injection-site reactions or events associated with GH therapy such as arthralgia, headache, and peripheral edema. In the extension trial, the overall discontinuation rate was 18.7%, with adverse-event frequency comparable to the initial phase.

Common Side Effects

  • Injection-site reactions
  • Itching (pruritus)
  • Arthralgia and myalgia
  • Peripheral edema

Metabolic Monitoring

  • Tesamorelin raises IGF-1 levels; monitoring for IGF-1 elevations during therapy is recommended.
  • Patients should be monitored periodically for impaired glucose tolerance or diabetes. In trials, glucose parameter changes over 52 weeks were not clinically significant and similar to those at 26 weeks; hyperglycemia frequency was similar between groups, including in patients on INSTI-based regimens.
  • Diabetic patients should be monitored for development or worsening of retinopathy.

Liver

Tesamorelin has not been linked to serum aminotransferase elevations or clinically apparent acute liver injury; in some studies it was associated with decreases in preexisting ALT elevations (liver injury likelihood score E, unlikely cause).

Hypersensitivity

Monitor for signs and symptoms of hypersensitivity reactions (pruritus, erythema, flushing, urticaria, rash). The formulation contains mannitol (55 mg per dose); it should not be used in patients with mannitol allergy.

Contraindications

  • Disruption of the hypothalamic-pituitary axis (hypophysectomy, hypopituitarism, pituitary tumor/surgery, head irradiation, or head trauma)
  • Active malignancy
  • Pregnancy

Cautions

Use with caution in patients with breathing problems, lung disease, carpal tunnel syndrome, diabetes, edema, history of heart surgery, retinopathy, history of stomach surgery, or trauma. Potential rare adverse events include stimulation of malignant tumor growth, glucose intolerance, diabetes, and hypersensitivity reactions.

Limitations

  • Long-term cardiovascular safety has not been established.
  • Safety and efficacy have not been established in children.
  • Immunogenicity affects pharmacokinetics, and age is an intrinsic factor affecting pharmacokinetics/pharmacodynamics.
  • High cost plus lack of long-term safety and adherence data are cited as practical limitations.

Reconstitution and handling

Formulation

Tesamorelin is supplied as a lyophilized powder (as tesamorelin acetate) requiring reconstitution before subcutaneous injection. The marketed lyophilized powder dose contains 1.1 mg tesamorelin acetate, and the formulation contains mannitol (55 mg per dose). Since 2019, only the 2-mg per vial formulation (Egrifta SV) is available in the US; given as a 1.4-mg dose it demonstrated comparable bioavailability to the older 1-mg/vial formulation (Egrifta). It is provided in two forms with different dosages (Egrifta SV and Egrifta WR).

Dosing

  • The recommended dose is 2 mg daily by subcutaneous injection.
  • It is administered subcutaneously into the abdomen once daily.
  • In healthy-subject studies, tesamorelin was tested at 1 mg and 2 mg doses.

Administration Notes

  • Rotate injection sites, using a new needle and syringe each time.
  • Avoid injecting into scar tissue, hard bumps, bruises, or the belly button.
  • Tesamorelin may sometimes be given at home to patients who do not need to be in a hospital or clinic.

Practical Consideration

Because VAT reaccumulates after discontinuation and benefits do not persist beyond treatment, ongoing daily administration is required to maintain the reduction in abdominal fat.

Sources

Ordered by evidence quality — the strongest first.

  1. Clinical Review Report: Tesamorelin (Egrifta) - NCBI Bookshelf(opens in a new tab)
    Tier 1Web · ncbi.nlm.nih.gov
  2. Efficacy and Safety of Tesamorelin in People with HIV on Integrase Inhibitors - PMC(opens in a new tab)
    Tier 1Web · pmc.ncbi.nlm.nih.gov
  3. Executive Summary - Clinical Review Report: Tesamorelin (Egrifta) - NCBI Bookshelf(opens in a new tab)
    Tier 1Web · ncbi.nlm.nih.gov
  4. Long-term safety (52 weeks) and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation [BASIC SCIENCE](opens in a new tab)
    Tier 1Web · natap.org
  5. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation(opens in a new tab)
    Tier 1Web · peptidesociety.org
  6. Tesamorelin(opens in a new tab)
    Tier 1Web · go.drugbank.com
  7. Tesamorelin - an overview | ScienceDirect Topics(opens in a new tab)
    Tier 1Web · sciencedirect.com
  8. Tesamorelin - LiverTox - NCBI Bookshelf(opens in a new tab)
    Tier 1Web · ncbi.nlm.nih.gov
  9. Tesamorelin Monograph for Professionals - Drugs.com(opens in a new tab)
    Tier 1Web · drugs.com
  10. Tesamorelin (subcutaneous route) - Side effects & dosage(opens in a new tab)
    Tier 1Web · mayoclinic.org · 2026
  11. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2026
  12. Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  13. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2024
  14. Tesamorelin improves fat quality independent of changes in fat quantity.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2021
  15. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2012
  16. Spotlight on tesamorelin in HIV-associated lipodystrophy.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2011
  17. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2011
  18. Tesamorelin.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2011
  19. CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S)(opens in a new tab)
    Tier 1Web · accessdata.fda.gov · 2009
  20. tesamorelin | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY(opens in a new tab)
    Tier 2Web · guidetopharmacology.org
  21. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2026
  22. Advances in the detection of growth hormone releasing hormone synthetic analogs.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2021
  23. Tesamorelin update.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2010
  24. Sermorelin: Mechanism, Benefits & Clinical Research | AgeMD(opens in a new tab)
    Tier 3Web · agemd.com
  25. Tesamorelin Dosing Guide: GHRH Analogue Research Protocols(opens in a new tab)
    Tier 3Web · parahealth.de
  26. The Ultimate Guide to Tesamorelin | Las Vegas | Sky Health(opens in a new tab)
    Tier 3Web · skyhealthnv.com
  27. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2026